The burgeoning popularity of semaglutide , initially for diabetes , is creating significant interest within the British Isles, prompting a notable shift in hormone trends. Access these compounds remains a complex challenge , with National Health Service coverage currently limited and specialist practices offering prescriptions at a premium . Concer